We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics (HAE) Expands VASCADE System Portfolio in Germany
Read MoreHide Full Article
Haemonetics (HAE - Free Report) recently announced that patients have been treated with the VASCADE MVP Venous Vascular Closure system in Germany. This marks the first use of the VASCADE system portfolio in a European country, having been extensively used in hospitals across the United States.
The expansion of the VASCADE system portfolio outside the United States represents a significant milestone for the company’s vascular closure business.
Significance of the VASCADE System
The VASCADE system is designed for "small-bore" femoral arterial and venous closure, generally used in interventional cardiology and peripheral vascular procedures. The VASCADE MVP system is designed for "mid-bore" multi-access femoral venous closure, generally used in electrophysiology procedures. Both closure devices are CE-marked under the EU-MDR (European Medical Device Regulations) for use in patients who have undergone catheter-based procedures with single or multiple access sites in one or both limbs.
Image Source: Zacks Investment Research
The VASCADE and VASCADE MVP systems include proprietary collapsible disc technology and a resorbable collagen patch to achieve hemostasis. The design of the systems saves time for hospital staff while helping patients reach hemostasis faster with fewer complications, on average, compared to manual compression.
More on the News
Haemonetics is preparing to further expand the VASCADE system portfolio in other markets outside the United States. Following the launch in Germany, the company has already introduced the VASCADE systems for use in Italy.
Moreover, an exclusive agreement with Japan Lifeline Co. Ltd was announced by Haemonetics for the distribution of the VASCADE MVP system in Japan. The launch is expected to occur later this year.
Per HAE’s representative, the global commercialization of the VASCADE portfolio fortifies the company’s prominence in improving hospital operations and raising standards of care for patients. The company is set to expand its presence in the global interventional cardiology and electrophysiology markets to meet the ongoing needs of physicians worldwide.
Industry Prospects
Per a Research report, the global peripheral vascular device market was valued at $6.5 billion in 2022 and is expected to witness a CAGR of 7.4% by 2030.
Recent Highlights
In the first quarter of fiscal 2024, Haemonetics received approval for VASCADE MVP in Japan and initiated the clinical use of its Vascular Closure products in key accounts in Germany and Italy. Going by the company's last update, the initial customer feedback was positive.
Price Performance
In the past six months, Shares of HAE have rallied 16% against the industry’s decline of 2.1%.
Zacks Rank and Other Key Picks
Haemonetics currently sports a Zacks Rank #1 (Strong Buy).
Shares of HealthEquity have risen 3.6% in the past year. Earnings estimates for HQY have remained constant at $1.92 for 2023 and moved from $2.47 to $2.48 for 2024 in the past 30 days.
HealthEquity’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 9.10%. In the last reported quarter, it posted an earnings surprise of 21.95%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.16 to 97 cents in the past 30 days. Shares of the company have increased 171.5% in the past year against the industry’s decline of 0.9%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 32.9% in the past year compared with the industry’s rise of 3.5%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Haemonetics (HAE) Expands VASCADE System Portfolio in Germany
Haemonetics (HAE - Free Report) recently announced that patients have been treated with the VASCADE MVP Venous Vascular Closure system in Germany. This marks the first use of the VASCADE system portfolio in a European country, having been extensively used in hospitals across the United States.
The expansion of the VASCADE system portfolio outside the United States represents a significant milestone for the company’s vascular closure business.
Significance of the VASCADE System
The VASCADE system is designed for "small-bore" femoral arterial and venous closure, generally used in interventional cardiology and peripheral vascular procedures. The VASCADE MVP system is designed for "mid-bore" multi-access femoral venous closure, generally used in electrophysiology procedures. Both closure devices are CE-marked under the EU-MDR (European Medical Device Regulations) for use in patients who have undergone catheter-based procedures with single or multiple access sites in one or both limbs.
Image Source: Zacks Investment Research
The VASCADE and VASCADE MVP systems include proprietary collapsible disc technology and a resorbable collagen patch to achieve hemostasis. The design of the systems saves time for hospital staff while helping patients reach hemostasis faster with fewer complications, on average, compared to manual compression.
More on the News
Haemonetics is preparing to further expand the VASCADE system portfolio in other markets outside the United States. Following the launch in Germany, the company has already introduced the VASCADE systems for use in Italy.
Moreover, an exclusive agreement with Japan Lifeline Co. Ltd was announced by Haemonetics for the distribution of the VASCADE MVP system in Japan. The launch is expected to occur later this year.
Per HAE’s representative, the global commercialization of the VASCADE portfolio fortifies the company’s prominence in improving hospital operations and raising standards of care for patients. The company is set to expand its presence in the global interventional cardiology and electrophysiology markets to meet the ongoing needs of physicians worldwide.
Industry Prospects
Per a Research report, the global peripheral vascular device market was valued at $6.5 billion in 2022 and is expected to witness a CAGR of 7.4% by 2030.
Recent Highlights
In the first quarter of fiscal 2024, Haemonetics received approval for VASCADE MVP in Japan and initiated the clinical use of its Vascular Closure products in key accounts in Germany and Italy. Going by the company's last update, the initial customer feedback was positive.
Price Performance
In the past six months, Shares of HAE have rallied 16% against the industry’s decline of 2.1%.
Zacks Rank and Other Key Picks
Haemonetics currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are HealthEquity (HQY - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of HealthEquity have risen 3.6% in the past year. Earnings estimates for HQY have remained constant at $1.92 for 2023 and moved from $2.47 to $2.48 for 2024 in the past 30 days.
HealthEquity’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 9.10%. In the last reported quarter, it posted an earnings surprise of 21.95%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.16 to 97 cents in the past 30 days. Shares of the company have increased 171.5% in the past year against the industry’s decline of 0.9%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s 2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 32.9% in the past year compared with the industry’s rise of 3.5%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.